SBFM

MKT CAP:$5M

Sunshine Biopharma, Inc.

Market Cap

$5M

Healthcare·Drug Manufacturers - Specialty & Generic·🇨🇦 Canada·NASDAQ

Healthcare·Drug·🇨🇦·NASDAQ

Stock Price

$1.00-$0.28 (-21.88%)

Apr 21, 2026

Company Details

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to...

CEO

Steve N. Slilaty

IPO Date

Feb 15, 2022

Website

www.sunshinebiopharma.com

Key Metrics TTM

Revenue

$36M

+4.1% YoY

Net Income

-$6M

EPS (Diluted)

-$8.89

Free Cash Flow

-$5M

Revenue / Share

$8.73

Gross Margin

33.5%

Operating Margin

-12.3%

Net Margin

-16.5%

FCF Margin

-14.8%

P/S

0.1x

P/E

—

Earnings Reports

FY 2025

Apr 3, 2026

$36M+4.1%EPS -$1.44

Q4 2025

Apr 3, 2026

$9M-10.6%EPS -$0.46

Q3 2025

Nov 13, 2025

$9M+11.6%EPS -$0.19

Q2 2025

Aug 12, 2025

$9M+1.2%EPS -$7.80

Q1 2025

May 15, 2025

$9M+18.0%EPS -$0.44

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$122.6K	$62.8K	-$1M
Q2 22	$150.3K	$75.6K	-$695.8K
Q3 22	$132.8K	$67.0K	-$2M
Q4 22	$4M	$1M	-$23M
Q1 23	$5M	$2M	-$2M
Q2 23	$6M	$2M	-$1M
Q3 23	$6M	$2M	-$779.5K
Q4 23	$8M	$3M	-$1M
Q1 24	$8M	$2M	-$1M
Q2 24	$9M	$2M	-$1M
Q3 24	$8M	$3M	-$1M
Q4 24	$10M	$3M	-$2M
Q1 25	$9M	$3M	-$1M
Q2 25	$9M	$3M	-$992.8K
Q3 25	$9M	$3M	-$532.0K
Q4 25	$9M	$3M	-$2M

Valuation

Quarter	P/S	P/E
Q1 22	88.1x	—
Q2 22	36.6x	—
Q3 22	21.2x	—
Q4 22	2.3x	—
Q1 23	1.1x	—
Q2 23	0.5x	—
Q3 23	0.3x	—
Q4 23	0.2x	—
Q1 24	0.1x	—
Q2 24	0.0x	—
Q3 24	0.0x	—
Q4 24	0.0x	—
Q1 25	0.0x	—
Q2 25	0.0x	—
Q3 25	0.0x	—
Q4 25	0.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$1M	-$1M
Q2 22	-$573.8K	-$573.8K
Q3 22	-$1M	-$1M
Q4 22	-$2M	-$2M
Q1 23	-$2M	-$2M
Q2 23	-$4M	-$4M
Q3 23	-$457.3K	-$469.1K
Q4 23	-$3M	-$3M
Q1 24	-$3M	-$4M
Q2 24	-$5M	-$5M
Q3 24	-$1M	-$2M
Q4 24	-$3M	-$4M
Q1 25	-$2M	-$2M
Q2 25	-$1M	-$2M
Q3 25	-$727.8K	-$761.9K
Q4 25	-$2M	-$845.8K

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$194.0K
Q1 23	$178.4K
Q2 23	$294.2K
Q3 23	$11.8K
Q4 23	$303.7K
Q1 24	$699.8K
Q2 24	$572.2K
Q3 24	$609.5K
Q4 24	$439.3K
Q1 25	$212.0K
Q2 25	$550.2K
Q3 25	$34.1K
Q4 25	$770.2K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+206.2%	+2.3%
Q2 22	+184.3%	+91.7%
Q3 22	+163.6%	+238.6%
Q4 22	+4528.7%	+7385.5%
Q1 23	+3890.4%	+399.5%
Q2 23	+3599.7%	+677.1%
Q3 23	+4385.9%	+264.0%
Q4 23	+94.9%	-67.5%
Q1 24	+54.1%	+32.3%
Q2 24	+67.3%	+60.8%
Q3 24	+41.6%	+41.6%
Q4 24	+24.9%	+31.2%
Q1 25	+18.0%	+14.7%
Q2 25	+1.2%	-1.6%
Q3 25	+11.6%	+4.3%
Q4 25	-10.6%	-12.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	0.0%
Q2 22	$0	0.0%
Q3 22	$0	0.0%
Q4 22	$0	0.0%
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$0	0.0%
Q1 24	$0	0.0%
Q2 24	$0	0.0%
Q3 24	$0	0.0%
Q4 24	$0	0.0%
Q1 25	$0	0.0%
Q2 25	$0	0.0%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	$361.7K	$826.4K	$95.0K
Q2 22	$45.9K	$635.5K	$87.7K
Q3 22	$362.5K	$1M	$217.7K
Q4 22	$41.8K	$6M	$177.7K
Q1 23	$432.9K	$3M	$127.9K
Q2 23	$368.6K	$2M	$133.2K
Q3 23	$238.0K	$2M	$241.9K
Q4 23	$816.3K	$3M	$231.3K
Q1 24	$222.0K	$3M	$198.0K
Q2 24	$436.2K	$3M	$256.3K
Q3 24	$126.4K	$3M	$282.7K
Q4 24	$149.3K	$5M	$203.2K
Q1 25	$215.3K	$3M	$398.4K
Q2 25	$196.2K	$4M	$201.7K
Q3 25	$119.3K	$3M	$235.2K
Q4 25	—	$8M	$308.7K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$13M	$7.6K	$13M
Q2 22	$42M	$7.6K	$42M
Q3 22	$41M	$7.6K	$41M
Q4 22	$22M	$0	$22M
Q1 23	$19M	$0	$19M
Q2 23	$20M	$0	$20M
Q3 23	$19M	$0	$19M
Q4 23	$16M	$0	$16M
Q1 24	$17M	$0	$17M
Q2 24	$12M	$0	$12M
Q3 24	$12M	$0	$12M
Q4 24	$10M	$0	$10M
Q1 25	$8M	$70.5K	$8M
Q2 25	$10M	$0	$10M
Q3 25	$9M	$0	$9M
Q4 25	$9M	$0	$9M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	5M	+47.1%	+140.3%
Q2 22	8K	-99.8%	-99.7%
Q3 22	189K	+2283.3%	-92.6%
Q4 22	23M	+11859.4%	+530.0%
Q1 23	11K	-100.0%	-99.8%
Q2 23	1M	+11408.4%	+15902.0%
Q3 23	13K	-99.0%	-93.2%
Q4 23	12K	-7.0%	-99.9%
Q1 24	32K	+168.6%	+191.0%
Q2 24	50K	+55.1%	-96.1%
Q3 24	1M	+2450.0%	+9771.5%
Q4 24	3M	+103.5%	+21508.0%
Q1 25	3M	+4.8%	+8329.8%
Q2 25	225K	-91.7%	+352.1%
Q3 25	5M	+1969.2%	+266.9%
Q4 25	4M	-10.6%	+61.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$40.9K	3
Q2 22	$50.1K	3
Q3 22	$44.3K	3
Q4 22	$1M	3
Q1 23	$2M	3
Q2 23	$2M	3
Q3 23	$2M	3
Q4 23	$174.6K	44
Q1 24	$171.4K	44
Q2 24	$211.4K	44
Q3 24	$191.7K	44
Q4 24	$184.5K	52
Q1 25	$171.2K	52
Q2 25	$181.0K	52
Q3 25	$181.1K	52
Q4 25	$165.0K	52

Revenue / Employee